首页> 美国卫生研究院文献>other >IL-7 Permits Th1/Tc1 Maturation And Promotes Ex-Vivo Expansion of Cord Blood T Cells: A Critical Step Toward Adoptive Immunotherapy After Cord Blood Transplantation
【2h】

IL-7 Permits Th1/Tc1 Maturation And Promotes Ex-Vivo Expansion of Cord Blood T Cells: A Critical Step Toward Adoptive Immunotherapy After Cord Blood Transplantation

机译:IL-7许可证的Th1 / Tc1的成熟和促进脐带血性T细胞的离体扩增:一个关键步骤走向过继免疫脐血移植后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Donor leukocyte infusions (DLI) in the allogeneic hematopoietic transplant setting can provide a clinically relevant boost of immunity to reduce opportunistic infections and to increase graft-versus-leukemia activity. Despite significant advances in applicability, DLI has not been available for single unit recipients of unrelated cord blood transplant (UCBT). Ex-vivo expansion of cord blood T cells can be achieved with IL-2 and CD3/CD28 co-stimulatory beads. However, significant apoptosis occurs in proliferating T cells, diminishing the yield and skewing the CD4/CD8 ratio in the T cell population, jeopardizing the potential efficacy of DLI. In this study, we demonstrate that IL-7 not only reduces apoptosis of activated T lymphocytes and enhances their proliferation, but also promotes functional maturation leading to secretion of interferon-gamma and other key cytokines. Recognizing that infused T lymphocytes will need to meet microbial antigens in secondary lymphoid organs to generate effectors, we also show that expansion with IL-7 promotes the preservation of a polyclonal broad T cell receptor repertoire and a surface phenotype that favors lymph node homing. Expanded lymphocytes lack alloreactivity against recipient and other allogeneic cells indicating a favorable safety profile from graft-versus-host disease. Nevertheless, expanded T cells can be primed subsequently against lymphoid and myeloid leukemia cells to generate tumor-specific cytotoxic T cells. Taken together, our findings offer a major step in fulfilling critical numerical and biological requirements to quickly generate a DLI product ex vivo, using a negligible fraction of a cord blood graft that provides a flexible adoptive immunotherapy platform for both for children and adults.

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号